categori
arenavirus
defin
nation
institut
allergi
infecti
diseas
niaid
human
pathogen
could
weapon
bioterrorist
mani
deadli
virus
requir
biosafeti
contain
laboratori
work
limit
tradit
laboratori
highthroughput
screen
ht
identif
small
molecul
inhibitor
reason
relat
new
world
arenaviru
tacarib
viru
ident
viru
amino
acid
level
use
ht
campaign
approxim
small
molecul
compound
screen
tacarib
virusinduc
cytopath
effect
cpe
assay
compound
identifi
screen
show
antivir
activ
specif
tacarib
viru
also
categori
new
world
arenavirus
machupo
guanarito
drug
resist
variant
isol
suggest
compound
act
inhibit
viral
protein
viral
glycoprotein
cellular
toxic
mechan
lead
compound
chosen
drug
develop
potent
select
compound
good
bioavail
demonstr
protect
antivir
efficaci
tacarib
mous
challeng
model
seri
compound
repres
new
class
inhibitor
may
warrant
develop
potenti
inclus
strateg
stockpil
nation
institut
allergi
infecti
diseas
niaid
center
diseas
control
prevent
cdc
classifi
number
virus
potenti
agent
bioterror
http
wwwbtcdcgovagentagentlistadministr
serv
effect
treat
diseas
patient
protect
suspect
expos
pathogen
postexposur
prophylaxi
assist
time
contain
outbreak
arenavirus
envelop
virus
genom
consist
two
singlestrand
rna
segment
design
small
kb
larg
l
kb
ambisens
code
arrang
southern
rna
segment
encod
major
structur
protein
nucleocapsid
protein
np
precursor
envelop
protein
gpc
encod
two
envelop
glycoprotein
extern
transmembran
beyer
et
al
froeschk
et
al
kunz
et
al
lenz
et
al
l
rna
segment
encod
rna
polymeras
protein
l
kda
protein
z
protein
put
regulatori
function
bowen
et
al
form
tetramer
surfac
glycoprotein
spike
respons
viru
entri
target
host
cell
arenavirida
famili
divid
two
group
accord
sequencebas
phylogeni
old
world
group
endem
africa
includ
human
pathogen
lymphocyt
choriomening
lcm
viru
lassa
viru
new
world
group
endem
latin
america
divid
three
clade
clade
b
includ
addit
tacarib
amapari
virus
categori
human
pathogen
virus
argentin
hemorrhag
fever
machupo
bolivian
hemorrhag
fever
guanarito
venezuelan
hemorrhag
fever
brazilian
hemorrhag
fever
categori
virus
capabl
caus
sever
often
fatal
hemorrhag
fever
diseas
human
rodent
natur
host
arenavirus
although
tacarib
viru
found
bat
arenavirus
characterist
produc
chronic
virem
infect
natur
host
rawl
et
al
turn
shed
viru
urin
fece
ultim
infect
human
close
contact
infect
materi
either
aerosol
direct
contact
skin
abras
cut
natur
histori
human
diseas
determin
pathogen
viru
geograph
distribut
habitat
habit
rodent
reservoir
host
natur
humanrod
interact
child
peter
current
virusspecif
treatment
approv
use
arenaviru
hemorrhag
fever
number
vitro
inhibitor
arenaviru
replic
report
literatur
candurra
et
al
glushakova
et
al
petkevich
et
al
wachsman
et
al
rawl
et
al
modest
activ
signific
toxic
ribavirin
compound
shown
partial
efficaci
arenaviru
infect
high
level
undesir
secondari
reaction
enria
maiztegui
ribavirin
nonimmunosuppress
nucleosid
analogu
broad
antivir
properti
jahrl
ribavirin
shown
reduc
mortal
lassa
fever
highrisk
patient
jahrl
treatment
viral
hemorrhag
fever
current
consist
primarili
support
care
enria
maiztegui
garcia
et
al
leifer
et
al
arenaviru
hemorrhag
fever
studi
undertaken
toward
develop
vaccin
argentin
hemorrhag
fever
ahf
caus
viru
liveattenu
vaccin
call
candid
evalu
control
trial
among
agricultur
worker
ahfendem
area
appear
reduc
number
report
ahf
case
seriou
side
effect
enria
et
al
known
candid
vaccin
would
use
arenaviru
hemorrhag
fever
tacarib
viru
biosafeti
new
world
arenaviru
nwa
found
clade
b
phylogenet
relat
categori
nwa
machupo
guanarito
tacarib
viru
ident
viru
amino
acid
level
four
viral
protein
order
screen
inhibitor
nwa
highthroughput
screen
ht
assay
viru
replic
develop
use
tacarib
viru
surrog
categori
nwa
small
molecul
librari
screen
use
ht
assay
lead
seri
chosen
base
drug
properti
seri
optim
iter
chemistri
result
ident
highli
activ
specif
small
molecul
inhibitor
tacarib
viru
select
activ
human
pathogen
nwa
machupo
guanarito
molecul
demonstr
favor
pharmacodynam
properti
permit
demonstr
vivo
antiarenaviru
activ
newborn
mous
model
chemic
librari
screen
repres
broad
wellbalanc
collect
compound
accumul
number
year
varieti
distinct
sourc
librari
achiev
broad
coverag
across
properti
space
involv
follow
chemic
descriptor
calcul
logarithm
noctanolwat
partit
coeffici
clogp
polar
wateraccess
surfac
area
psa
globular
three
dimension
structur
molecular
weight
averag
da
vero
african
green
monkey
kidney
epitheli
atcc
cell
grown
eagl
minimum
essenti
medium
mem
gibco
supplement
mm
lglutamin
gml
gentamicin
heatinactiv
fetal
bovin
serum
fb
infect
medium
im
serum
concentr
reduc
cell
human
carcinoma
larynx
epitheli
atcc
cultur
mem
contain
heatinactiv
fb
penicillinstreptomycin
cell
human
normal
lung
fibroblast
atcc
cultur
mem
contain
heatinactiv
fb
penicillinstreptomycin
lglutamin
invitrogen
nonessenti
amino
acid
invitrogen
sodium
pyruv
invitrogen
sodium
bicarbon
cell
epitheli
african
green
monkey
kidney
atcc
cultur
mem
penicillinstreptomycin
lglutamin
nonessenti
amino
acid
sodium
pyruv
sodium
bicarbon
gml
trypsin
serum
viru
infect
cell
line
incub
c
co
respiratori
syncyti
viru
rsv
isol
lymphocyt
choriomening
viru
lcmv
armstrong
isol
cytomegaloviru
cmv
isol
herp
simplex
viru
ko
isol
vaccinia
viru
strain
wr
tacarib
viru
strain
trvl
rotaviru
strain
wa
obtain
atcc
candid
amapari
bean
obtain
dr
robert
tesh
univers
texa
medic
branch
galveston
tx
work
done
virus
lassa
josiah
strain
machupo
carvallo
strain
guanarito
strain
romero
strain
well
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
conduct
collabor
usamriid
fort
detrick
md
viral
cpe
assay
use
evalu
antivir
effect
compound
tacarib
viru
vero
cell
vaccin
viru
vero
cell
amapari
viru
vero
cell
sarscov
vero
cell
vero
cell
rsv
cell
vaccinia
viru
vero
cell
rotaviru
enzymelink
immunosorb
assay
elisa
use
evalu
antivir
effect
compound
cmv
cell
lcmv
vero
cell
assay
carri
appropri
media
contain
heatinactiv
fb
ninetysixwel
cell
cultur
plate
seed
h
use
cell
per
well
vero
cell
per
well
cell
per
well
compound
suscept
test
compound
solubil
dmso
ad
duplic
well
final
concentr
final
concentr
dmso
assay
viru
stock
titrat
separ
experi
determin
concentr
result
destruct
cell
monolay
cpe
assay
day
rotaviru
vaccinia
day
sarscov
rsv
tacarib
viru
candid
vaccin
viru
amapari
viru
concentr
gener
elisa
signal
optic
densiti
nm
od
day
lcmv
day
cmv
preestablish
dilut
viru
pfu
tacarib
viru
ad
well
contain
serial
dilut
compound
uninfect
cell
cell
receiv
viru
without
compound
includ
assay
plate
addit
refer
agent
avail
includ
assay
plate
gancyclovir
cmv
sigma
ribavirin
lcmv
rsv
sigma
rifampicin
vaccinia
viru
sigma
plate
incub
c
co
either
day
rotaviru
lcmv
vaccinia
viru
day
tacarib
viru
amapari
viru
candid
viru
sarscov
rsv
cmv
sarscov
rotaviru
vaccinia
viru
rsv
tacarib
viru
amapari
viru
candid
vaccin
viru
infect
plate
process
crystal
violet
stain
plate
infect
cmv
lcmv
process
elisa
analysi
crystal
violet
stain
plate
fix
glutaraldehyd
stain
crystal
violet
rins
dri
optic
densiti
nm
od
measur
use
micropl
reader
elisa
analysi
medium
lcmv
cmvinfect
plate
remov
cell
fix
methanol
fisher
ca
hplc
grade
min
room
temperatur
methanol
solut
remov
plate
wash
three
time
pb
nonspecif
bind
site
block
addit
l
superblock
block
buffer
pierc
h
c
block
agent
remov
well
wash
three
time
pb
thirti
microlit
dilut
lcmv
nuclear
protein
np
specif
monoclon
antibodi
gener
gift
juan
carlo
de
la
torr
scripp
research
institut
la
jolla
ca
l
dilut
cmv
protein
uniqu
long
gene
product
specif
cocktail
monoclon
antibodi
dako
superblock
block
buffer
contain
ad
follow
h
incub
c
primari
antibodi
solut
remov
well
wash
three
time
pb
contain
forti
microlit
goat
antimous
horseradish
peroxidas
conjug
monoclon
antibodi
biorad
dilut
lcmv
cmv
superblock
block
buffer
contain
ad
well
plate
incub
h
c
secondari
antibodi
solut
remov
well
wash
five
time
pb
assay
develop
min
addit
l
substrat
sigma
quantifi
peroxidas
activ
od
result
reaction
product
measur
use
molecular
devic
kinet
micropl
reader
nm
filter
antivir
activ
tacarib
viru
evalu
three
method
cpe
assay
plaqu
reduct
viru
yield
inhibit
assay
ht
cpe
assay
vero
cell
plate
confluenc
plate
test
compound
per
plate
librari
ad
well
final
concentr
tacarib
viru
ad
viru
dilut
would
result
cpe
day
multipl
infect
moi
approxim
seed
stock
pfuml
final
volum
plate
incub
c
co
day
fix
glutaraldehyd
stain
crystal
violet
extent
viru
cpe
quantifi
spectrometr
od
use
envis
micropl
reader
inhibitori
activ
compound
calcul
subtract
od
test
compound
well
averag
od
virusinfect
cell
well
divid
averag
od
mockinfect
cell
well
result
repres
percent
protect
tacarib
viru
cpe
activ
confer
compound
hit
assay
defin
compound
inhibit
virusinduc
cpe
greater
test
concentr
hit
possess
chemic
tractabl
evalu
inhibitori
potenc
inhibitori
concentr
ec
valu
determin
plot
compound
inhibitori
activ
follow
cpe
assay
across
eight
compound
concentr
determin
perform
duplic
plaqu
reduct
assay
vero
cell
monolay
grown
sixwel
plate
infect
pfuwel
absenc
presenc
variou
concentr
compound
h
viru
adsorpt
c
residu
inoculum
replac
mix
seaplaqu
agaros
deioniz
water
mem
plaqu
count
day
incub
c
ec
calcul
compound
concentr
requir
reduc
viru
plaqu
number
condit
usamriid
plaqu
reduct
assay
lassa
machupo
guanarito
virus
perform
follow
pfu
viru
use
infect
vero
cell
viru
adsorpt
cell
monolay
rins
overlaid
complet
medium
contain
agaros
either
lack
test
compound
differ
concentr
rang
day
incub
c
monolay
stain
neutral
red
number
plaqu
count
viru
yield
reduct
assay
vero
cell
grown
plate
infect
tacarib
viru
moi
presenc
differ
concentr
compound
two
well
per
concentr
h
incub
c
viru
harvest
viru
yield
determin
plaqu
format
vero
cell
ec
valu
calcul
indic
similar
calcul
perform
determin
ec
ec
cell
viabil
measur
cell
prolifer
assay
determin
compound
effect
cellular
function
cytotox
concentr
cc
could
calcul
ratio
valu
ec
refer
select
index
si
cc
ec
two
type
assay
use
determin
cytotox
one
colorimetr
method
measur
reduct
bromid
mtt
use
fluorimetri
measur
reduct
resazurin
alamar
blue
method
produc
similar
data
confluent
well
rapidli
divid
cell
cultur
plate
expos
differ
concentr
compound
two
well
concentr
use
incub
condit
equival
use
antivir
assay
sever
potent
compound
identifi
tacarib
ht
group
sever
cluster
structur
type
one
cluster
compound
fw
repres
prototyp
base
antivir
activ
chemic
tractabl
chosen
develop
retrosynthet
analysi
determin
librari
analogu
could
prepar
converg
singl
synthet
step
combin
isocyan
acyl
hydrazid
use
chemistri
analogu
prepar
potent
examin
vitro
metabol
stabil
liver
extract
describ
experi
design
character
mechan
action
antivir
compound
vero
cell
grown
well
cultur
plate
medium
remov
cell
reach
confluenc
replac
infect
medium
cell
infect
tacarib
viru
moi
h
adsorpt
viral
inoculum
remov
replac
fresh
infect
medium
duplic
well
treat
h
prior
infect
time
infect
specif
time
postinfect
h
pi
control
infect
cell
cultur
treat
drug
vehicl
dmso
remov
h
postabsorpt
monolay
wash
twice
cold
pbsm
replac
fresh
infect
medium
cell
harvest
h
pi
titrat
describ
separ
experi
vero
cell
plate
well
dish
infect
tacarib
viru
moi
absorpt
carri
h
ad
h
h
infect
infect
h
follow
infect
follow
drug
addit
viru
infect
monolay
wash
three
time
complet
media
four
hour
follow
last
drug
addit
monolay
overlaid
agaros
without
compound
plaqu
develop
day
postinfect
monolay
fix
crystal
violet
stain
plaqu
number
count
experi
design
test
bindingfus
inhibitori
properti
toward
tacarib
viru
vero
cell
grown
mem
fetal
calf
serum
experi
cell
grown
confluenc
cultur
plate
one
set
tube
tacarib
viru
pfu
treat
dmso
serial
dilut
tenfold
infect
medium
treat
specif
concentr
pfu
pfu
dmso
pfu
dmso
final
dmso
concentr
well
anoth
set
tube
tacarib
viru
pfu
treat
serial
dilut
tenfold
infect
medium
suspens
plate
well
adsorpt
one
hour
inocula
remov
overlaid
seaplaqu
agaros
mem
plate
incub
c
cytopath
effect
observ
dmso
control
well
cell
fix
gluteraldehyd
stain
crystal
violet
plaqu
visual
anoth
assay
employ
test
bind
properti
prefus
fprotein
virion
dialysi
experi
purifi
tacarib
viru
pfu
incub
dmso
suspens
dialyz
overnight
c
dialysi
chamber
twentyfour
hour
postdialysi
viral
suspens
titrat
vero
cell
one
hour
postadsorpt
inocula
remov
seaplaqu
agaros
mem
overlay
appli
plate
incub
c
cytopath
effect
observ
cell
fix
gluteraldehyd
stain
crystal
violet
confirm
absenc
free
drug
dialys
virusdrug
sampl
viru
spike
dialys
mixtur
time
infect
plaqu
develop
describ
initi
singl
plaqu
wt
tacarib
viru
isol
plaquepurif
vero
cell
sixwel
plate
infect
pfuwel
wt
tacarib
viru
h
c
follow
viru
adsorpt
inoculum
remov
well
overlaid
seaplaqu
agaros
mem
incub
c
plaqu
visibl
day
four
plaqu
pick
amplifi
vero
cell
plate
cpe
develop
day
virusinfect
cell
extract
harvest
scrape
cell
media
collect
ml
microcentrifug
tube
plaquepurifi
isol
amplifi
mm
plate
viru
stock
origin
one
viru
plaqu
titrat
isol
compoundresist
tacarib
viru
variant
wild
type
plaquepurifi
isol
titrat
presenc
describ
vero
cell
sixwel
plate
infect
pfuwel
media
contain
h
cell
overlaid
seaplaqu
agaros
mem
contain
incub
plaqu
form
plaqu
pick
use
infect
vero
cell
plate
without
compound
cpe
develop
infect
well
harvest
drugresist
isol
titrat
plate
log
dilut
start
l
pure
viru
stock
without
compound
mutant
went
sever
round
plaqu
purif
final
viru
stock
made
rna
extract
tacarib
wt
isol
four
drug
resist
isol
dr
use
revers
transcript
pcr
primer
specif
gpc
tacforward
gcctaactgaaccaggtgaatc
tacrevers
taagacttccgcaccacagg
tacarib
use
amplif
sequenc
two
test
use
assess
compound
solubl
solubl
cell
cultur
medium
without
variou
concentr
serum
solubl
aqueou
buffer
ph
solut
stir
overnight
filter
amicon
centrifre
column
mw
cut
remov
potenti
precipit
compound
compound
bound
protein
compound
quantifi
lcm
uv
spectrometri
vitro
metabol
stabil
determin
absorpt
system
exton
pa
use
g
supernat
homogen
liver
variou
speci
sourc
oxid
conjug
enzym
eg
cytochrom
udpglucuronosyl
transferas
known
primari
pathway
biotransform
drug
metabol
stabil
measur
persist
parent
compound
incub
time
fraction
mass
spectrometri
briefli
human
rat
mous
guinea
pig
fraction
obtain
xenotech
lenexa
ks
reaction
mixtur
minu
cofactor
cocktail
prepar
mgml
liver
fraction
mm
nadph
mm
udpga
mm
pap
mm
gsh
mm
potassium
phosphat
ph
mm
magnesium
chlorid
test
articl
equilibr
c
min
aliquot
reaction
mixtur
taken
neg
control
reaction
initi
addit
cofactor
cocktail
reaction
mixtur
reaction
mixtur
neg
control
incub
shake
water
bath
c
aliquot
l
withdrawn
triplic
min
combin
l
icecold
acetonitriledh
termin
reaction
sampl
analyz
via
lcmsm
natur
log
percent
remain
plot
versu
time
linear
fit
use
determin
rate
constant
fit
truncat
percent
remain
test
articl
less
elimin
halfliv
associ
disappear
test
control
articl
determin
compar
rel
metabol
stabil
exploratori
bacteri
mutagen
assay
ame
test
use
assess
potenti
compound
genotox
assay
util
typhimurium
tester
strain
singl
base
pair
mutat
frame
shift
mutat
without
metabol
activ
arochlorinduc
rat
liver
describ
previous
maron
ame
analysi
oral
pharmacokinet
select
compound
perform
spraguedawley
rat
singl
dose
studi
serum
sampl
taken
h
period
newborn
mice
pk
evalu
day
old
balbc
mice
dose
intraperiton
ip
serum
sampl
taken
h
period
min
min
min
h
h
h
h
h
h
l
aliquot
plasma
combin
l
acetonitril
contain
intern
standard
ngml
tolbutamid
ml
centrifug
tube
sampl
vortex
centrifug
rpm
min
l
aliquot
result
supernat
transfer
hplc
vial
analysi
plasma
level
compound
determin
lcmsm
pharmacokinet
paramet
determin
use
winnolin
softwar
determin
toler
newborn
day
old
balbc
mice
given
ip
dosag
vehicl
mgkgday
day
assess
clinic
statu
daili
test
efficaci
tacarib
newborn
mous
model
four
day
old
balbc
mice
eight
per
dose
group
challeng
pfu
tacarib
viru
per
mous
ip
inject
death
end
point
mice
either
treat
placebo
vehicl
ribavirin
mp
biomed
administ
ip
mgkg
day
day
administ
ip
mgkg
day
mgkg
twice
day
day
mice
monitor
daili
weigh
everi
day
throughout
studi
mice
show
sign
morbid
euthan
co
asphyxi
anim
studi
conform
institut
laboratori
anim
research
approv
appropri
iacuc
review
current
recogn
viral
speci
arenavirida
famili
clegg
bowen
virus
classifi
two
group
old
world
lassalcm
arenavirus
new
world
tacarib
complex
group
new
world
tacarib
complex
compris
three
phylogenet
lineag
design
clade
ac
clade
b
includ
prototyp
tacarib
viru
amapari
viru
four
south
american
categori
pathogen
machupo
guanarito
tacarib
viru
ident
viru
amino
acid
level
four
viral
protein
clegg
work
authent
categori
arenavirus
requir
maximum
laboratori
contain
therefor
present
signific
logist
safeti
issu
sinc
tacarib
viru
close
relat
categori
pathogen
chosen
surrog
nwa
develop
ht
assay
screen
inhibitor
viru
replic
sinc
tacarib
viru
grow
well
cell
cultur
caus
clear
virusinduc
cytopath
effect
cpe
robust
ht
cpe
assay
develop
plate
cpe
assay
whole
cell
assay
allow
calcul
select
index
compound
identif
inhibitor
essenti
step
viru
life
cycl
compound
screen
tacarib
viru
ht
assay
hit
identifi
hit
rate
hit
ec
valu
hit
qualifi
base
four
criteria
chemic
tractabl
ii
inhibitori
potenc
iii
inhibitori
select
iv
antivir
specif
chemic
tractabl
compound
defin
entiti
synthet
access
use
reason
chemic
methodolog
possess
chemic
stabl
function
potenti
druglik
qualiti
hit
pass
medicin
chemistri
filter
evalu
inhibitori
potenc
ec
cc
select
index
si
valu
determin
assess
whether
hit
select
inhibitor
hit
si
valu
least
consid
hit
identifi
compound
exhibit
characterist
qualiti
hit
compound
chemic
tractabl
ec
valu
si
valu
among
qualiti
hit
sever
cluster
structur
type
one
structur
type
chosen
develop
repres
prototyp
seri
da
compound
structur
shown
fig
seen
tabl
submicromolar
potenc
good
select
antivir
specif
tacarib
viru
well
categori
nwa
evalu
viru
yield
reduct
assay
tacarib
viru
produc
ec
ec
valu
respect
cc
valu
vero
cell
repres
solubl
limit
compound
cell
cultur
media
give
select
index
activ
tacarib
viru
test
multipl
cell
line
ec
valu
similar
achiev
vero
cell
data
shown
test
sever
arenavirus
show
inhibitori
activ
owa
either
lcm
viru
authent
lassa
viru
tabl
drug
also
lack
activ
nwa
amapari
viru
surpris
result
given
result
repres
averag
least
two
independ
determin
repres
limit
compound
solubl
close
phylogenet
relationship
amapari
tacarib
virus
clegg
bowen
et
al
discrep
later
discuss
follow
sequenc
nwa
howev
importantli
show
potent
antivir
activ
vaccin
strain
viru
candid
well
machupo
guanarito
virus
tabl
specif
antivir
activ
exhibit
determin
test
number
relat
unrel
virus
show
activ
varieti
unrel
dna
hsv
cmv
vaccinia
viru
rna
rsv
rotaviru
sarscov
virus
singl
cycl
h
time
addit
experi
done
determin
viru
replic
cycl
exert
antivir
activ
effect
tacarib
viru
yield
determin
follow
addit
compound
vero
cell
cultur
variou
time
infect
ad
h
infect
h
viru
adsorpt
h
sever
time
postinfect
drug
kept
follow
sequenti
addit
infect
cell
cultur
entir
time
experi
control
infect
cultur
treat
drug
vehicl
dmso
h
postinfect
sampl
collect
viru
yield
determin
plaqu
assay
shown
fig
exert
inhibitori
effect
earli
stage
viru
life
cycl
addit
time
point
postinfect
effect
viru
yield
data
suggest
earli
stage
inhibitor
viru
replic
result
confirm
second
type
time
addit
experi
experi
compound
spike
cultur
medium
h
h
infect
h
infect
h
postinfect
h
remov
cultur
wash
remov
residu
compound
overlaid
agaros
viru
plaqu
number
determin
day
postinfect
data
fig
show
compound
ad
viru
adsorpt
h
effect
plaqu
format
compound
ad
h
adsorptionentri
process
dramat
reduc
tacarib
plaqu
format
data
consist
adsorptionentri
inhibitor
two
approach
taken
determin
bind
intact
virion
first
experi
pfu
purifi
tacarib
viru
incub
dmso
dialyz
overnight
c
titrat
viru
titrat
dialyz
bag
origin
incub
drug
pfu
viru
titrat
dmso
vehicl
dialyz
bag
data
shown
drug
biolog
detect
dialysi
bag
origin
contain
drug
measur
incap
viru
plu
drug
dialyz
mixtur
inhibit
freshli
ad
tacarib
viru
pfu
data
suggest
bind
intact
virion
slow
dissoci
constant
second
experi
fig
tacarib
viru
incub
test
tube
dmso
serial
dilut
perform
sampl
ad
specifi
dilut
repres
concentr
drug
expect
follow
sampl
dilut
viru
compound
dilut
media
compound
concentr
reach
concentr
without
inhibitori
effect
unless
compound
capabl
bind
viru
test
viru
without
compound
initi
tube
also
dilut
media
compound
concentr
correspond
found
tube
viru
compound
dilut
togeth
ad
viru
dilut
titrat
vero
cell
show
present
excess
initi
tube
carri
two
addit
dilut
specif
viru
bind
inhibit
viru
infect
wherea
drug
ad
specifi
dilut
viru
inhibit
degre
viru
dilut
drug
data
shown
data
suggest
bind
least
slow
k
intact
protein
present
tacarib
viru
expect
mutat
rate
rna
virus
high
resist
variant
virion
common
approach
determin
target
antivir
isol
viru
resist
antivir
map
site
resist
viru
variant
reduc
suscept
isol
wild
type
tacarib
viru
stock
plate
presenc
observ
frequenc
drug
resist
dr
variant
expect
rna
virus
sixteen
dr
isol
four
independ
wild
type
tacarib
viru
stock
isol
plaqu
purifi
three
time
dr
isol
test
abil
grow
presenc
growth
dr
isol
unaffect
presenc
concentr
complet
inhibit
wild
type
tacarib
viru
replic
data
shown
isol
confirm
drug
resist
viru
variant
strongli
suggest
act
direct
antivir
inhibitor
determin
genet
basi
resist
molecular
target
rna
isol
wild
type
dr
isol
base
time
addit
experi
suspect
viral
glycoprotein
might
target
entir
glycoprotein
precursor
gpc
region
segment
sequenc
sequenc
analysi
perform
four
wild
type
isol
wt
four
dr
isol
deriv
drug
select
appli
correspond
parent
wild
type
isol
dr
wt
dr
wt
dr
wt
dr
wt
sequenc
analysi
show
gpc
gene
four
parent
wild
type
isol
ident
sequenc
compar
gpc
sequenc
four
drug
resist
variant
possess
singl
nucleotid
chang
case
result
amino
acid
chang
fig
show
locat
mutat
locat
around
transmembran
domain
sequenc
align
region
contain
chang
present
fig
singl
chang
dr
amino
acid
posit
dr
amino
acid
dr
amino
acid
dr
amino
acid
similarli
conserv
l
never
clade
b
new
world
arenaviru
conserv
among
clade
b
nwa
similarli
conserv
one
except
amapari
viru
encod
leucin
posit
chang
amapari
viru
may
explain
lack
suscept
lie
near
nand
ctermin
limit
put
transmembran
domain
region
known
play
vital
role
envelop
viru
fusion
bagai
lamb
harman
et
al
jeetendra
et
al
west
et
al
yao
compan
taken
togeth
data
suggest
amino
acid
chang
arenaviru
either
posit
suffici
confer
reduc
suscept
consist
propos
fusion
inhibit
mechan
suggest
virolog
experi
preliminari
data
show
demonstr
interest
antivir
activ
specif
poor
pharmacokinet
pk
properti
rodent
mous
rat
data
shown
order
improv
pk
properti
lead
optim
chemistri
campaign
initi
object
optim
program
develop
compound
possess
attribut
consist
ultim
drug
product
profil
lead
optim
activ
compris
seri
iter
involv
design
chemic
synthesi
analog
lead
structur
follow
seri
biolog
physiochem
pharmacolog
evalu
new
compound
chemic
analog
flow
compound
evalu
paradigm
involv
first
vitro
virolog
cytotox
assess
follow
seri
evalu
list
vitro
metabol
stabil
solubl
exploratori
bacteri
mutagenesi
pharmacokinet
assess
one
hundr
sixtyf
analogu
prepar
potent
examin
vitro
metabol
liver
extract
stabl
dose
rat
emerg
potent
oral
bioavail
repres
compound
structur
sulfonyl
show
fig
test
drug
resist
tacarib
mutant
gener
mutant
elicit
crossresist
suggest
compound
target
area
data
shown
activ
tacarib
machupo
guanarito
virus
similar
seen
tabl
tabl
metabol
stabil
test
liver
extract
rat
mous
human
guinea
pig
found
stabl
human
follow
mous
rat
guinea
pig
respect
tabl
analysi
oral
pharmacokinet
potent
antivir
activ
nwa
good
druglik
properti
next
step
test
abil
inhibit
nwainduc
diseas
anim
model
categori
agent
experi
requir
contain
howev
effort
obtain
initi
readout
tacarib
viru
challeng
model
newborn
mice
establish
prepar
studi
pk
toler
experi
perform
newborn
mice
prior
conduct
efficaci
trial
newborn
old
balbc
mice
dose
ip
mgkg
blood
sampl
collect
analysi
rel
vitro
antivir
concentr
requir
inhibit
tacarib
viru
cpe
ec
ngml
mean
plasma
concentr
newborn
mice
well
level
prolong
period
time
h
h
dose
data
shown
model
drug
deliv
via
ip
rout
due
difficulti
perform
multipl
oral
gavag
newborn
mice
test
toler
newborn
mice
given
ip
dosag
rang
mgkgday
day
dosag
mgkgday
day
well
toler
newborn
mice
clinic
sign
toxic
mice
gain
weight
rate
control
mice
data
shown
highest
test
concentr
mgkgday
use
tacarib
anim
efficaci
studi
fig
effect
newborn
mice
challeng
tacarib
viru
four
day
old
balbc
mice
infect
ip
tacarib
viru
treat
daili
day
vehicl
control
ribavirin
mgkg
twice
day
bid
mgkg
day
sid
mgkg
shown
percent
survivor
treatment
group
day
infect
signific
p
valu
determin
use
fisher
exact
test
drug
level
halflif
shown
pk
studi
newborn
mice
equival
seen
rat
serum
level
seem
suffici
perform
proofofconcept
anim
studi
tacarib
anim
model
four
day
old
mice
challeng
tacarib
viru
treat
placebo
ribavirin
control
result
fig
demonstr
show
efficaci
tacarib
infect
newborn
mice
surviv
delay
death
similar
drug
control
ribavirin
taken
togeth
data
suggest
promis
appropri
drug
candid
advanc
definit
anim
studi
guinea
pig
primat
challeng
authent
nwa
guanarito
virus
treat
variou
time
postinfect
prophylat
success
ht
medicin
chemistri
program
nwa
antivir
drug
candid
identifi
drug
potent
select
inhibit
nwa
virus
vitro
includ
three
niaidcdc
categori
virus
machupo
guanarito
virus
compound
also
evalu
stabil
liver
extract
pharmacokinet
properti
found
metabol
stabl
oral
bioavail
preliminari
anim
efficaci
studi
show
signific
protect
tacarib
viru
induc
diseas
newborn
mice
mechan
action
studi
appar
seri
compound
target
viral
entri
inhibitor
studi
undertaken
elucid
experiment
affin
precis
bind
site
also
fit
drug
resist
variant
analyz
vitro
vivo
dialysi
dilut
experi
fig
appar
drug
bind
viru
carri
dilut
phenomenon
could
potenti
effect
titrat
viru
sampl
experi
howev
time
addit
experi
enough
drug
carri
due
high
dilut
affect
titer
ad
h
infect
fig
sinc
better
stabil
thought
metabol
occur
methyl
group
aromat
ring
fig
benzyl
posit
suscept
oxid
benzyl
hydrogen
present
fig
oxid
block
thu
elimin
fastest
metabol
pathway
addit
difluoromethoxi
group
gave
compound
increas
stabil
reduc
antivir
activ
tacarib
newborn
mous
model
mice
appear
die
neurolog
diseas
indic
hind
quarter
paralysi
known
whether
cross
blood
brain
barrier
bbb
ribavirin
cross
bbb
adult
speci
howev
extent
ribavirin
cross
barrier
newborn
mice
unknown
also
drug
level
halflif
drug
candid
given
ip
newborn
mice
good
oral
dose
rat
serum
level
compound
get
brain
may
compromis
abil
obtain
complet
protect
model
appropri
anim
model
hemorrhag
fever
caus
arenavirus
guinea
pig
nonhuman
primat
viru
replic
predominantli
spleen
lymph
node
bone
marrow
caus
hemorrhag
diathesi
guinea
pig
model
well
establish
machupo
guanarito
viru
diseas
repres
best
small
anim
model
evalu
preclin
studi
hall
et
al
peter
et
al
guinea
pig
infect
pathogen
strain
viru
develop
fatal
diseas
akin
human
ahf
weissenbach
et
al
mani
report
role
transmembran
function
viral
fusion
protein
case
influenza
viru
hemagglutinin
clear
transmembran
anchor
requir
full
fusion
activ
harman
et
al
contrast
specif
sequenc
requir
within
transmembran
domain
identifi
exampl
human
immunodefici
viru
hiv
type
murin
leukemia
viru
foami
virus
coronaviru
newcastl
diseas
viru
measl
viru
harman
et
al
base
drug
resist
variant
gener
studi
class
compound
target
envelop
protein
mutat
elicit
reduc
suscept
drug
aris
around
transmembran
region
fig
drug
target
interact
viru
envelop
cellular
receptor
repres
new
class
antivir
drug
hiv
therapi
entri
inhibitor
recent
rais
great
interest
activ
multidrug
resist
virus
new
antivir
hiv
recent
approv
fda
call
enfuvirtid
enfuvirtid
fuzeon
potent
fusion
inhibitor
block
format
sixhelix
bundl
thu
prevent
membran
fusion
kinomoto
et
al
enfuvirtid
success
improv
virolog
immunolog
respons
treatmentexperienc
hivinfect
patient
oldfield
et
al
sever
compound
counter
hiv
entri
differ
development
stage
among
attach
inhibitor
inhibitor
glycoprotein
gp
interact
pro
tnx
bm
coreceptor
inhibitor
subdivid
target
castagna
et
al
success
enfuvirtid
other
develop
pathway
proof
viru
entri
inhibitor
use
treat
viral
diseas
human
also
potenti
prophylact
use
sinc
drug
appear
bind
viru
fig
would
prevent
infect
viru
entri
inhibitor
demonstr
protect
given
prophylact
cianci
et
al
indic
pursu
determin
feasibl
result
present
show
potent
specif
inhibitor
new
world
arenavirus
includ
categori
hemorrhag
fever
virus
machupo
guanarito
importantli
target
viru
entri
cell
serv
viabl
target
antivir
develop
sinc
viru
infect
complet
inhibit
concentr
nanomolar
rang
target
would
seem
access
extrem
sensit
reagent
disrupt
role
infect
process
therefor
import
defin
mechan
involv
mediat
inhibit
